Does Retatrutide Cause Muscle Loss? What the DEXA Data Shows

Introduction

Losing 28% of your body weight sounds straightforwardly good — until you ask what, exactly, is coming off. Scale weight doesn't distinguish between fat and muscle. A pound lost from your thigh could be fat tissue or it could be the muscle that powers your stairs, your squat, your metabolism at rest.

This question matters more for retatrutide than for almost any other weight loss drug, simply because of the scale of weight loss involved. Losing 28.3% of body weight (the TRIUMPH-1 average) is a magnitude previously seen mainly with bariatric surgery — and bariatric surgery has a well-documented lean mass loss problem.

The honest answer, based on the best available evidence: some muscle loss happens with retatrutide, as it does with virtually every significant weight loss intervention. The real question is how much, whether it's proportionate, and what you can do about it.

What the Actual Data Shows

The most rigorous evidence on retatrutide and body composition comes from a prespecified substudy of the Phase 2 trial, published in The Lancet Diabetes & Endocrinology. Researchers used DEXA (dual-energy X-ray absorptiometry) — the clinical gold standard for distinguishing fat mass from lean mass — to scan 189 participants with type 2 diabetes before and after treatment.

What they found:

The fat loss index (a measure of what proportion of total weight loss came from fat versus lean tissue) was 64.6% across the pooled 4mg, 8mg, and 12mg dose groups. In plain terms: roughly two-thirds of the weight lost was fat, and about 35% was lean mass.

The researchers' own conclusion was direct: this proportion is "similar to other obesity treatments." Retatrutide did not show a disproportionate lean mass penalty despite producing substantially more total weight loss than other GLP-1-class drugs.

Important context about this data:

This substudy was conducted in participants with type 2 diabetes, not the general obesity population this site primarily covers. T2D and general obesity populations can have different baseline body composition and may respond somewhat differently to treatment. TRIUMPH-1 and TRIUMPH-4 — the Phase 3 trials in general obesity populations most relevant to most readers — have not yet published body composition substudy results.

TRIUMPH-3 (the sleep apnea trial) was designed with a planned DEXA substudy in approximately 100 participants, intended to measure body composition specifically in a broader population. Results from this substudy have not yet been published as of June 2026.

A Note on Conflicting Numbers Online

If you search for "retatrutide muscle loss," you'll find a range of claimed percentages — some sources cite 74% fat / 26% lean, others 75-80% fat / 20-25% lean, others 85-90% fat / 10-15% lean. These numbers are inconsistent with each other and, as far as we can determine, are not traceable to a published, peer-reviewed source specific to retatrutide's Phase 3 trials.

We are not going to repeat unverified figures here. The one number we can confidently cite — 64.6% fat loss index (35.4% lean mass) — comes from an actual published substudy in a peer-reviewed journal, in a specific population (T2D), at a specific timepoint. Until TRIUMPH-3's body composition substudy or other Phase 3 data is published, that's the most reliable data point available.

Why Some Lean Mass Loss Is Expected (and Not Necessarily Bad)

Note: figures for diet, other GLP-1 drugs, and bariatric surgery come from separate studies using varying methodologies and populations; direct comparison should be treated as approximate, not exact.

Some lean mass loss accompanies essentially every method of significant weight loss — pharmacological, surgical, or behavioral. The body doesn't lose weight in a way that's 100% selective for fat tissue. Muscle, along with some water, bone mineral, and organ mass, is included in what DEXA scans classify as "lean mass" — it isn't only skeletal muscle.

The relevant clinical question isn't "does any lean mass loss occur" (it does, with everything), but whether the proportion is in a normal, expected range — and the available data suggests retatrutide's proportion is consistent with what's seen elsewhere in this drug class.

Does Retatrutide's Glucagon Component Help or Hurt Muscle Preservation?

This is a legitimate point of scientific uncertainty, and the honest answer is: it could go either way, and the current data doesn't fully resolve it.

The case for glucagon helping: Glucagon receptor activation increases lipolysis (fat breakdown) and fatty acid oxidation. In theory, a drug that more aggressively mobilizes fat stores for energy could spare lean tissue from being broken down for fuel — since the body has an alternative energy source readily available.

The case for glucagon hurting: Glucagon also has counter-regulatory effects on protein metabolism. Chronic glucagon receptor activation can, in some physiological contexts, increase amino acid mobilization from muscle tissue (gluconeogenic substrate), which could theoretically accelerate lean mass loss rather than prevent it.

The published Phase 2 substudy result — a fat loss index "similar to other obesity treatments" — suggests these two competing effects roughly cancel out, or that neither dominates strongly enough to produce a meaningfully different lean mass outcome compared to GLP-1/GIP-only drugs. This is reassuring in one sense (no disproportionate harm) but doesn't support claims that retatrutide is specifically muscle-sparing in a way other drugs aren't.

What You Can Actually Do to Protect Muscle Mass

Regardless of which weight loss drug someone uses, the same evidence-based strategies apply for minimizing lean mass loss during significant weight loss.

Adequate protein intake. Most clinical guidance for patients undergoing substantial pharmacological weight loss suggests targeting 1.0–1.2 grams of protein per kilogram of body weight daily — higher than typical dietary recommendations. Protein provides the amino acids needed to signal muscle protein synthesis and helps offset the catabolic pressure of caloric deficit.

Resistance training. Mechanical loading is the primary stimulus that tells the body to preserve (or build) muscle tissue rather than break it down. Even two to three resistance sessions per week, targeting major muscle groups, has been shown in weight loss research to meaningfully reduce the proportion of lean mass lost compared to no resistance training.

Avoiding excessive caloric deficit. While appetite suppression from retatrutide can lead to very low spontaneous intake, an extremely aggressive deficit increases the relative contribution of muscle breakdown to total weight loss. Working with a physician or dietitian to ensure intake doesn't fall too far below maintenance needs can help.

Adequate sleep. Sleep deprivation independently increases muscle protein breakdown and reduces the muscle-protective effect of resistance training and protein intake. This is a frequently overlooked variable in body composition outcomes.

Monitoring beyond the scale. Tracking body composition — through DEXA scans, bioelectrical impedance devices, or even simple proxies like strength benchmarks and progress photos — gives more useful feedback than scale weight alone. A 30-pound loss that's mostly fat looks and functions very differently than a 30-pound loss that's a meaningful fraction muscle.

Putting the Numbers in Perspective

If a patient on 12mg retatrutide loses 28.3% of body weight (the TRIUMPH-1 average) and roughly 35% of that is lean mass (extrapolating from the T2D Phase 2 substudy, with the caveat that this hasn't been confirmed in the general obesity population), the practical math looks something like this: for someone starting at 250 lbs who loses 70 lbs, approximately 45–46 lbs would be fat mass and approximately 24–25 lbs would be lean mass.

That's a substantial amount of lean mass to lose in absolute terms — which is exactly why protein intake and resistance training aren't optional extras for patients pursuing this level of weight loss. They're a core part of doing it well rather than just doing it.

For comparison, the same proportional loss applied to tirzepatide's average 22.5% weight loss (SURMOUNT-1) would produce a smaller absolute lean mass loss simply because the total weight lost is smaller — not necessarily because the proportion lost is different.

Conclusion

Retatrutide does cause some lean mass loss — that much is consistent with every significant weight loss intervention, pharmacological or otherwise. The best available evidence, a DEXA-confirmed Phase 2 substudy in patients with type 2 diabetes, found a fat loss index of 64.6%, meaning roughly 35% of weight lost was lean mass — a proportion researchers describe as comparable to other obesity treatments, not worse.

What's still unknown is whether this proportion holds in the general obesity population studied in TRIUMPH-1 and TRIUMPH-4, where total weight loss is substantially higher than the Phase 2 T2D cohort. TRIUMPH-3's planned body composition substudy should eventually clarify this for a broader population.

In the meantime, the practical takeaway doesn't change much regardless of the exact percentage: adequate protein intake and resistance training are the two most evidence-backed tools for minimizing lean mass loss on any significant weight loss therapy, including retatrutide.

For a complete picture of what to expect on retatrutide, see our complete side effects guide.

Sources

• Coskun T, et al. "Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial." The Lancet Diabetes & Endocrinology, 2025.
• Rosenstock J, Frias J, Jastreboff AM, et al. "Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes." The Lancet, 2023;402:529-544.
• Giblin K, et al. "Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials." Diabetes, Obesity and Metabolism, 2026;28(1):83-93.
• Jastreboff AM, et al. TRIUMPH-1 Phase 3 topline results (May 21, 2026).